AlzeCure Pharma
Alzecure Pharma: Comment on Study Results (Redeye)
2021-04-20 07:20
Yesterday, Alzecure Pharma announced positive results from its phase 1b study with drug candidate ACD440 in neuropathic pain. Redeye gives its first reflections to this news and raises Base Case.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se